The impact of diabetes on workforce participation: results from a national household sample.

OBJECTIVE Diabetes is a highly prevalent condition that results in substantial morbidity and premature mortality. We investigated how diabetes-associated mortality, disability, early retirement, and work absenteeism impacts workforce participation. DATA SOURCE We used the Health and Retirement Study (HRS), a national household sample of adults aged 51-61 in 1992, as a data source. STUDY DESIGN We conducted cross-sectional analyses on the baseline HRS data, and longitudinal analyses using data from eight years of follow-up. We used two-part regression models to estimate the adjusted impact of diabetes on workforce participation, and then estimated the economic impact of diabetes-related losses in productivity. PRINCIPAL FINDINGS Diabetes is a significant predictor of lost productivity. The incremental lost income due to diabetes by 1992 was 60.0 billion US dollars over an average diabetes duration of 9.7 years. From 1992 to 2000, diabetes was responsible for 4.4 billion US dollars in lost income due to early retirement, 0.5 billion US dollars due to increased sick days, 31.7 billion US dollars due to disability, and 22.0 US dollars billion in lost income due to premature mortality, for a total of 58.6 billion dollars in lost productivity, or 7.3 billion US dollars per year. CONCLUSIONS In the U.S. population of adults born between 1931 and 1941, diabetes is associated with a profound negative impact on economic productivity. By 1992, an estimated 60 billion US dollars in lost productivity was associated with diabetes; additional annual losses averaged 7.3 billion US dollars over the next eight years, totaling about 120 billion US dollars by the year 2000. Given the rising prevalence of diabetes, these costs are likely to increase substantially unless countered by better public health or medical interventions.

[1]  A. Krolewski,et al.  Mortality from cardiovascular diseases among diabetics , 1977, Diabetologia.

[2]  Anke Richter,et al.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.

[3]  A. Barsky,et al.  Forgetting, fabricating, and telescoping: the instability of the medical history. , 2002, Archives of internal medicine.

[4]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[5]  H. Birnbaum,et al.  Productivity and medical costs of diabetes in a large employer population. , 2002, Diabetes care.

[6]  J. Cauley,et al.  Diabetes and incidence of functional disability in older women. , 2002, Diabetes care.

[7]  L S Geiss,et al.  Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. , 2001, Diabetes care.

[8]  Suzanne G. Leveille,et al.  Diabetes and physical disability among older U.S. adults. , 2000, Diabetes care.

[9]  C. O'muircheartaigh,et al.  Telescoping of landmark events: implications for survey research. , 2000, Public opinion quarterly.

[10]  R. de Marco,et al.  Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. , 1999, Diabetes care.

[11]  R. Baumgartner,et al.  Prevalences of Type 2 Diabetes, the Insulin Resistance Syndrome, and Coronary Heart Disease in an Elderly, Biethnic Population , 1998, Diabetes Care.

[12]  W. Manning,et al.  The logged dependent variable, heteroscedasticity, and the retransformation problem. , 1998, Journal of health economics.

[13]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[14]  N. Ray,et al.  Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.

[15]  R. Hayward,et al.  Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes , 1997, Annals of Internal Medicine.

[16]  D. Hadden,et al.  Macrovascular disease and hyperglycaemia: 10‐year survival analysis in Type 2 diabetes mellitus: the Belfast diet study , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[17]  K. Alberti The Clinical Implications of Impaired Glucose Tolerance , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[18]  C. Weel,et al.  Cardiovascular Morbidity and Mortality in Type 2 Diabetic Patients: a 22‐year Historical Cohort Study in Dutch General Practice , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[19]  R. Suzman,et al.  An Overview of the Health and Retirement Study , 1995 .

[20]  J. Tuomilehto,et al.  Diabetes and the risk of stroke. , 1993, Journal of diabetes and its complications.

[21]  E. Barrett-Connor,et al.  Prevalence of Cardiovascular and Renal Complications in Older Adults With Normal or Impaired Glucose Tolerance or NIDDM: A population-based study , 1993, Diabetes Care.

[22]  T. Orchard,et al.  Diabetes Mellitus and Macrovascular Complications: An epidemiological perspective , 1992, Diabetes Care.

[23]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[24]  M. Harris Epidemiology of diabetes mellitus among the elderly in the United States. , 1990, Clinics in geriatric medicine.

[25]  G A Colditz,et al.  The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.

[26]  D. Reed,et al.  Diabetes and the risk of stroke. The Honolulu Heart Program. , 1987, JAMA.

[27]  C. Morris,et al.  A Comparison of Alternative Models for the Demand for Medical Care , 1983 .

[28]  P. McNamara,et al.  Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.